Summary The recent use of interleukin 2 (IL-2) and interleukin 4 (IL-4) single cytokine modified tumour cells in rodent models has demonstrated a potential use of these cytokines to produce autologous cancer cell vaccines. Here we compare the potential therapeutic benefit of transduction with IL-2 or IL-4 alone, and combined IL-2 + IL-4 in B16F1O cells, a murine malignant melanoma of poor immunogenicity. Transduction of B16F1O cells (MHC class I and II negative) to express either IL-2 or IL-4 alone delays the formation of tumours, IL-4 being more effective than IL-2. However, combined expression of IL-2 + IL4 reduces tumorigenicity more than either cytokine alone. The eventual formation of tumours may result from loss of gene expression, and preliminary results suggest methylation of the retroviral long terminal repeat (LTR), rather than loss of the transduced DNA sequences. Histological examination of tumours expressing either IL-2 or IL-4 alone shows a non-specific inflammatory reaction with an increased tissue infiltrate of immune effectors (monocytes/macrophages, lymphocytes, granulocytes) localised around the tumour. In comparison, when cells expressing combined IL-2 + IL-4 were injected there were more granulocytes present, and perhaps more importantly, these were mainly localised within the tumour. The benefit of combined IL-2 + IL-4 expression results from a local rather than systemic effect as the growth of tumours from cells expressing IL-2 or IL-4 alone injected at distant sites was comparable with a single inoculation of cells expressing either cytokine alone. However, when cells expressing single cytokines IL-2 or IL-4 were mixed and injected at the same site, in comparison with the clonal population of cells expressing combined IL-2 + IL-4, tumour growth was characteristic of IL-4 alone rather than IL-2 + IL-4. Treatment of established tumours with a single injection of lethally irradiated tumour cells expressing IL-2 + IL-4 was sufficient to either reject tumours, or at least delay further tumour development. Furthermore, treatment stimulated an initial non-specific immune reaction that lead to a systemic immunity. Lethally irradiated wild-type cells were also successful in treating some established tumours, although this did not induce any systemic immunity. However, although successful in treatment studies, neither wild-type nor combined IL-2 + IL-4 expressing cells were able to vaccinate animals against a subsequent challenge with live wild-type tumour. These results indicate a potential therapeutic benefit with the use of combination IL-2 + IL-4 transduction of autologous cancer cells.
The early observations in rodent models that the immunological response of host to tumour challenge could be affected by prior exposure to the tumour suggested the possibility of a specific host anti-tumour response (Klein et al., 1960; Hewitt et al., 1976) . Such studies led to the use of autologous cancer cells alone, and in combination with non-specific immuno stimulants (bacille Calmette-Guerin, Corynebacterium parvum), as vaccines to augment anti-tumour immunity. However, these strategies were only occasionally beneficial (Oettgen and Old, 1991) . Despite this lack of earlier success, recent studies involving the use of genetically modified tumour cells in rodent models have raised new possibilities for the potential of autologous cancer cell vaccines.
For autologous cancer cells to be of benefit in the treatment of human malignant disease, the tumour cells must be rendered more immunogenic to stimulate an antitumour immunity that results in systemic protection against further tumour growth. Although a number of different gene therapy strategies have been employed, including transduction with recombinant viral antigens (Fearon et al., 1988 Sugiura et al., 1988 , MHC molecules (Wallich et al., 1985) and immune co-stimulators (e.g. B7.1, B7.2, Baskar et al., 1993; Li et al., 1994) , the most popular to date has been transduction of tumour cells to express different cytokines. Using various rodent models these studies have demonstrated that transduction of tumour cells with genes for (Fearon et al., 1990; Gansbacher et al., 1990a; Patel et al., 1993) , Correspondence: SJ Hollingsworth Received 1 December 1995; accepted 25 January 1996 (Li et al., 1990; Golumbek et al., 1991; Patel et al., 1993) , IL-6 (Porgador et al., 1992) , IL-7 (Aoki et al., 1992) , interferon gamma (y-IFN, Watanabe et al., 1989; Gansbacher et al., 1990b; Porgador et al., 1993) , tumour necrosis factor alpha (TNF-a, Blankenstein et al., 1991; Teng et al., 1991) , granulocyte colony-stimulating factor (G-CSF, Colombo et al., 1991) and granulocyte-macrophage colony-stimulating factor (GM-CSF, Dranoff et al., 1993) can significantly reduce tumorigenicity in syngeneic hosts. Of perhaps greater importance, tumour cells modified to express such cytokines can also induce systemic immunity as mice vaccinated with transduced cells have been shown to reject a subsequent challenge of parental (non-transduced) cells, and in some cases an established tumour.
These studies have produced encouraging results, but they also indicate that it will be of critical importance to identify which cytokines and combinations of cytokines are best able to stimulate an anti-tumour response. Furthermore, these studies have clearly indicated a relationship between levels of transduced cytokine gene expression and therapeutic benefit. However, for a clinical application, whereas autologous tumour cells expressing high levels of the cytokine transgene are desirable, this may be difficult to achieve in practice. Transduction of tumour cells to express multiple cytokine genes is more feasible than obtaining clones of a high transgene expression. A synergistic action between cytokines would therefore potentially provide a more feasible option for clinical application. Despite this, no studies have examined the effects of transduction with more than one cytokine, although some have directly compared the effects of different single cytokines in the same model (Dranoff et al., 1993; Patel et al., 1993 ). An (Markowitz et al., 1988) were grown in vitro as adherent monolayers in Dulbecco's modified Eagle medium (DMEM) with 10% newborn calf serum (NCS).
Vectors and infection protocol
The producer cell lines GP+ envAMI2-pBabeNeo-murine.IL-2 and GP + envAM12-pBabePuro-murine.IL-4 were a kind gift from Dr Mary Collins (Institute of Cancer Research, London); the pBabe vectors (Morgenstern and Land, 1990) were generated by Dr Hartmut Land (ICRF, London); and PA317-M3P-SVHygro was generated in our own laboratories (Gaken et al., 1992) . For infectious viral supernatant, adherent producer cells grown in DMEM +10% NCS were transferred to RPMI-1640 + 10% FCS and cell supernatants collected at a minimum of 4 hourly intervals, filtered (0.45 ,um filter) and polybrene was added to a final concentration of 4-8 ig ml-'. B16F10 cells were plated in RPMI-1640+ 10% FCS until adherent, then filtered viral supernatant added directly to the cells at 10-20 ml/plate/ round of infection with between four and ten rounds of infection. Following infection, cells were cultured in fresh medium (RPMI-1640 + 10% FCS) for a further 72 h before selection in either 1 mg ml-' G418 (500 jug ml-'), 2 jug ml-' puromycin, 150 ,ug ml-' hygromycin, or appropriate combinations. Drug-resistant cells were either ring cloned directly from plates (IL-2/clone 2, IL-4/clone 5), or trypsinised and frozen as a mixed population (M3P). For infection with both IL-2 and IL-4, a clone (IL-4/clone 4) was tested for cytokine secretion, infected with IL-2 viral supernatant, selected and ring cloned.
The cell lines expressing IL-2, IL-4 and IL-2+IL-4 were produced using 'pBabe' vectors (see above), and the emptyvector control transduced cell line used was produced using the 'M3P' vector (see above). However, as both vectors contain the same gag sequence the expression of viral protein in the transduced cell lines will be the same. (2) Cytokine/molecular analysis of explanted tumours The eventual formation of tumours might result from a loss of gene expression, mutation, recombination, translocation, or deletion of the inserted DNA sequences. Tumours were explanted at sacrifice, cultured and analysed by ELISA for cytokine expression, and PCR for the presence of the inserted DNA sequences. In all cases there was a significant reduction in the levels of cytokine expression in tumour explants compared with the original inoculated cells (see Table I ). PCR analysis, using primers encompassing the whole of the open reading frame of either IL-2 or IL-4, showed that the inserted DNA sequences were present. In preliminary studies, Figure 2b-d) . The beneficial effects of combined IL-2 + IL-4 expression probably result from a local rather than systemic effect. However, when cells expressing IL-2 and IL-4 alone were mixed (1:1; 0.5 x I05 of each cell type) and injected at the same site the formation of tumours was characteristic of cells expressing IL-4 alone rather than combined IL-2 + IL-4 (see Figure 2c , e, f). Although the local secretion of IL-4 would seem to affect the growth of tumour cells expressing IL-2 within this mixed population of cells, the synergistic effects of combined IL-2+IL-4 expression were not seen as compared with the clonal population of cells expressing combined IL-2+IL-4 (see Figure 2e ,f).
(6) Treatment of established B16FJO tumours As the expression of combined IL-2 + IL-4 was more beneficial than either cytokine alone, we further examined the ability of lethally irradiated tumour cells expressing combined IL-2 + IL-4 to treat animals with established wild-type tumours.
Lethal irradiation (10 000 rads y-irradiation) of B16F1O cells expressing combined IL-2 + IL-4 did not abrogate the expression of either IL-2 or IL-4 for at least 9 days after irradiation (Table IV) . Syngeneic C57B1/6 mice were injected subcutaneously with either 104 or 105 wild-type B16F1O Figure 3 . The levels of cytokine secretion were assayed as described in Materials and methods, and values are the mean of triplicate experiments. Colombo and Forni, 1994 In the present study, transduction of B16FIO cells to express IL-4 reduced tumorigenicity more than IL-2, confirming the work of others (Patel et al., 1993) . However, expression of combined IL-2+IL-4 delayed tumour formation considerably further. Cytokine expression appears to arrest tumour growth by stimulating a local infiltrate of nonspecific immune effector cells. Expression of IL-2 alone caused an increase in granulocyte infiltrates, although Patel et al., (1993) reported the infiltrate in IL-2-transduced FS29 tumours to be largely CD8+ lymphocytes. Transduction of B16FIO cells to express IL-4 caused an increased infiltrate of both granulocytes and macrophages. Similar infiltrates have been seen by others in IL-4-transduced tumours (murine plasmacytoma and murine adenocarcinoma, Tepper et al., 1989; murine renal cell carcinoma, Golumbek et al., 1991; murine fibrosarcoma, Patel et al., 1993) . Combined expression of IL-2+IL-4 produced a greater increase in the total number of infiltrating granulocytes, although there were fewer infiltrating macrophages than with IL-4 alone. Furthermore, in contrast to either cytokine alone, many of the granulocytes in the IL-2 + IL-4 tumours were actually Table II ) was granulocytic with little or no effect on lymphocyte infiltration. Furthermore, the eventual formation of tumours secreting combined IL-2 + IL-4 might also argue against a direct T-cell involvement. However, treatment of established tumours with combined IL-2 + IL-4 induced a protective immunity. Rejection of tumours can be due to direct killing by activated granulocytes (eg. neutrophils, eosinophils), whereas the induction and effector phases of memory require involvement of CD4+ and CD8+ cells (Colombo and Forni, 1994) . When tumour cells are engineered to express cytokines, the levels of cytokine released correlate with the intensity of tumour rejection. Colombo and Forni (1994) suggest that high levels of cytokine lead to the rapid disappearance of the tumour, which results in insufficient loading of antigenpresenting cells and so the memory effect is not induced. However, lower amounts of cytokines induce a slower reaction in which initial growth is followed by rejection, and so a significant amount of tumour-cell debris becomes available to antigen-presenting cells both in the tumour rejection site and the draining lymph nodes that have active T-cell areas. Thus, by an initial non-specific inflammatory reaction a systemic immunity may be induced, and this most likely explains the results we have obtained. Despite this, vaccination with lethally irradiated IL-2 + IL-4-expressing cells did not induce immune protection against a subsequent challenge with live wild-type tumour (see Figure 4) . However, this may be explained by a difference in the nature and extent of initial non-specific immune infiltration.
Lethally immune cell infiltrate crucial in the response to tumour)., with IL-9 producing only a hmited effect. When combined IL-2 + IL-4-expressing cells were injected the increased infiltrate was almost exclusively granulocytic, so it seems unlikely that the increased expression of IL-2 in these cells is providing an additional stimulus for a non-specific inflammatory response above that seen with IL-2 alone.
In studies using the CMS5 fibrosarcoma, Salvadonr et al.. (1994) suggest that IL-2 secretion by tumours prevents immunosuppression in tumour-bearing mice by maintaining normal signal transduction in T cells so facilitating the generation of an anti-tumour response. Tumour-derived IL-2 seems to function by directly activating p56"k associated with the IL-2 receptor #-chain decreasing the susceptibility of CD8 cells to inactivation signals delivered by tumour cells. However, in our studies the effect of IL-2 + IL-4 expression appears to be mediated by granulocytes rather than lymphocytes. Our results clearly suggest that transduction of tumour cells to express both IL-2+ IL-4 results in a synergistic action between the cytokines that is of greater therapeutic benefit than transduction with either cytokine alone.
